# The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

> **NCT06276764** · — · ENROLLING_BY_INVITATION · sponsor: **Adenocyte, LLC** · enrollment: 500 (estimated)

## Conditions studied

- IPMN, Pancreatic
- Pancreas Cancer
- Pancreatic Cyst

## Interventions

- **DIAGNOSTIC_TEST:** LINFU®

## Key facts

- **NCT ID:** NCT06276764
- **Lead sponsor:** Adenocyte, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-15
- **Primary completion:** 2034-09-30
- **Final completion:** 2034-12-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276764, "The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06276764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*